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Macrophage migration inhibitory factor (MIF), a proinflam-
matory cytokine, is considered an attractive therapeutic target
in multiple inflammatory and autoimmune disorders. In addi-
tion to its known biologic activities, MIF can also function as a
tautomerase. Several small molecules have been reported to be
effective inhibitors of MIF tautomerase activity in vitro. Herein
we employed a robust activity-based assay to identify different
classes of novel inhibitors of the catalytic and biological activi-
ties of MIF. Several novel chemical classes of inhibitors of the
catalytic activity ofMIFwith IC50 values in the range of 0.2–15.5
M were identified and validated. The interaction site and
mechanism of action of these inhibitors were defined using
structure-activity studies and a battery of biochemical and bio-
physical methods. MIF inhibitors emerging from these studies
could be divided into three categories based on theirmechanism
of action: 1)molecules that covalentlymodify the catalytic site at
the N-terminal proline residue, Pro1; 2) a novel class of catalytic
site inhibitors; and finally 3) molecules that disrupt the trimeric
structure of MIF. Importantly, all inhibitors demonstrated total
inhibition of MIF-mediated glucocorticoid overriding and AKT
phosphorylation, whereas ebselen, a trimer-disrupting inhibitor,
additionally acted as a potent hyperagonist in MIF-mediated che-
motactic migration. The identification of biologically active com-
poundswith known toxicity, pharmacokinetic properties, andbio-
logical activities in vivo should accelerate the development of
clinically relevant MIF inhibitors. Furthermore, the diversity of
chemical structures and mechanisms of action of our inhibitors
makes themidealmechanisticprobes forelucidating thestructure-
function relationships ofMIF and to further determine the role of
theoligomerization state and catalytic activity ofMIF in regulating
the function(s) ofMIF in health and disease.
Macrophage migration inhibitory factor (MIF)2 was discov-
ered in the 1960’s as a T-lymphocyte product that inhibits the
randommigration of macrophages during delayed-type hyper-
sensitivity responses (1, 2). Two decades later, a human MIF
genewas cloned (3). Yet, the biological activity ofMIF remained
ambiguous until the production of bioactiveMIF and anti-MIF
antibodies (4). Various biological activities have been attributed
to MIF, which is recognized as a major regulator of inflamma-
tion and a central upstream mediator of innate immune
responses (5, 6). MIF has broad regulatory properties and is
considered as a critical mediator of multiple disorders includ-
ing inflammatory and autoimmune diseases such as rheuma-
toid arthritis (7, 8), glomerulonephritis (9, 10), diabetes (11),
atherosclerosis (12), sepsis (13–15), asthma (16, 17), and acute
respiratory distress syndrome (18). Furthermore, recent stud-
ies have highlighted a role for MIF in tumorigenesis. Human
cancer tissues, including skin, brain, breast, colon, prostate,
and lung-derived tumors were observed to overexpress MIF,
and MIF levels correlated with tumor aggressiveness and
metastatic potential (19, 20). Therefore, MIF is considered a
viable therapeutic target for treating inflammatory diseases
and neoplasia.
In addition to its physiologic and pathophysiologic activities,
MIF is known to act as a tautomerase. This activity was initially
discovered during the investigation of melanin biosynthesis
(21). Subsequent studies revealed that MIF catalyzes the tau-
tomerization of D-dopachrome methyl ester (22–24) and
bears high structure, but not sequence, homology with bac-
terial tautomerases 4-oxalocrotonate-tautomerase, 5-car-
boxymethyl-2-hydroxymuconate isomerase, and chorismate
mutase (25–27). X-ray crystallography, NMR, and biophys-
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ical solution studies demonstrate that MIF exists predomi-
nantly as a homotrimer (28, 29). The tautomerase active site
is formed at the monomer-monomer interfaces within the
trimer and involves residues from two adjacent subunits.
The N-terminal proline (Pro1) with an unusual pKa (5.6 
0.1) (24) is commonly conserved in all of these tautomerases
and is essential for MIF tautomerase activity. Covalent mod-
ification of Pro1 or its replacement by serine, alanine, or
glycine totally abolishes the tautomerase activity of MIF (23,
30). p-Hydroxyphenylpyruvate and phenylpyruvate were
identified as potential tautomerase substrates (31). How-
ever, the kinetic parameters and the separate localization of
these substrates from MIF suggest that these molecules are
not physiological substrates of MIF.
Although the relationship between the catalytic activity and
biological function ofMIF is not yet fully understood, targeting
MIF tautomerase activity using small-molecule inhibitors has
emerged as an attractive strategy for inhibitingMIF proinflam-
matory activity and attenuating its biological activity in vitro
and in vivo (32, 33). The first MIF inhibitors were reported in
1999while trying to elucidate themechanismofMIF tautomer-
ase activity by testing the inhibitory effect of various structure
analogues of its substrate, D-dopachrome methyl ester (34).
Since then, different classes of tautomerase inhibitors have
been developed and were later shown to modulate biological
activities of MIF mediated by both its ability to act on intracel-
lular and extracellular signaling pathways (33, 35). As of today,
11 distinct chemical classes of MIF inhibitors have been devel-
oped (36) using different approaches, including (i) active site-
directed targeting; (ii) rational drug design, i.e. screening mol-
ecules that share structure similarity with known MIF
tautomerase substrates and inhibitors; and (iii) virtual high
throughput screening and computer-assisted drug design
approaches. The majority of the inhibitors described to date
exert their effects either by competingwith the substrate for the
catalytic site (e.g. ISO-1 and OXIM11) or via covalent modifi-
cation of the catalytic Pro1 residue (NAPQI (37) and 4-iodo-6-
phenylpyrimidine (4-IPP) (33)). For example, Senter and col-
leagues (37) identified a class of acetaminophen derivatives
(NAPQI), which form a covalent complex with MIF by react-
ing with the catalytic proline residue. NAPQI was shown to
block the ability of MIF to override the immunosuppressive
effect of dexamethasone on LPS-induced TNF production by
monocytes. A series of MIF inhibitors based on modifica-
tions of the scaffold of (S,R)-3-(4-hydroxyphenyl)-4,5-dihy-
dro-5-isoxazole acetic acid methyl ester (ISO-1) were devel-
oped (38–41). ISO-1 and some of its derivatives were shown
to block MIF tautomerase activity, inhibit TNF secretion
from macrophages upon stimulation with LPS, and increase
survival in models of sepsis (35, 42).
Recent studies from our group demonstrate that subtle con-
formational changes induced by mutations distal to the active
site result in significant inhibition of MIF tautomerase activity
(43, 44). These findings indicate that “allosteric” inhibition of
MIF enzymatic activity is possible, but may not be realized by
current efforts focused on targeting the active enzymatic site of
MIF using rational drug design strategies. Motivated by these
findings, we sought to develop a high throughput screening
(HTS) assay that would facilitate the identification of different
classes of MIF inhibitors, including novel irreversible, compet-
itive, and allosteric inhibitors, as well as molecules that may
inhibit MIF by blocking and/or disrupting its oligomerization
(i.e. trimer formation). To achieve this goal, we developed a
robust tautomerase activity-based HTS assay and screened
two chemical libraries containing a total of 15,440 com-
pounds. Twelve novel classes of MIF inhibitors were identi-
fied with IC50 values in the range of 0.2–15.5 M. Using
structure-activity studies, and a battery of biochemical and
biophysical methods, we were able to define the mechanism
of action for each of the three classes of inhibitors. These
results and their implications for developing therapeutic
strategies targetingMIF and elucidating the biochemical and
structural basis underlying its activities in health and disease
are presented and discussed.
EXPERIMENTAL PROCEDURES
Chemical Libraries
The NINDS Custom Collection II library from Microsource
Discovery Systems, Inc. and the Maybridge library were tested.
These libraries were composed of 1,040 and 14,400 biologically
active chemical molecules, respectively. The compounds were
arrayed in 384-well plates at a final concentration of 10 M and
a final DMSO concentration of 1%.
Compounds Used for Follow-up Studies
All hits generated from the Maybridge library were pur-
chased from Maybridge. Hexachlorophene (HCLP) and its
analogues (dichlorophene, bithionol, bis(2-hydroxyphenyl)-
methane, 2,2-diaminodiphenyl sulfide, 4,4-dichlorobenzo-
phenone, 2,2-sulfinyl-bis(4,6-dichlorophenol), 3,4-dihy-
droxy benzophenone, igrasan, benzophenone, and emodin)
were purchased from Sigma and Fluka and were of the high-
est purity available, whereas the analogue MDPI 894 was
purchased from Molecular Diversity Preservation Interna-
tional (MDPI), Basel, Switzerland.
Expression and Purification of HumanMIF and Its Mutants
(C56S, C59S, C80S, and N110C)
MIF was expressed by heat shock transformation of the
BL21/DE3 Escherichia coli strain (Stratagene) with the bacte-
rial expression vector pET11b containing the human (MIF)
gene under control of the T7 promoter. Four hours post-induc-
tion, the cells were harvested, re-suspended in lysis buffer (50
mM Tris-HCl, pH 7.4, 50 mM KCl, 5 mM MgAc, 0.1% NaN3),
sonicated, and centrifuged at 14,000 g for 20 min. The clari-
fied cell lysate was filtered, injected onto a MonoQ anion
exchange column (HiPrep 16/10 Q FF, GE Healthcare), and
eluted with a linear NaCl gradient in the elution buffer (25 mM
Tris-HCl, pH 7.4, 150 mM NaCl). The flow-through fractions
containing MIF were pooled and loaded onto a Superdex 75
16/60 (HiLoad 16/60, Superdex 75, GE Healthcare) gel filtra-
tion column. Fractions corresponding to MIF were combined,
dialyzed against 1 PBS, and filtered through a 0.2-m filter.
Recombinant MIF used for cellular studies was subjected to
LPS removal as described previously (45). Briefly, bacterial cell
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lysate was injected onto an anion exchange column. The flow-
through fractions containing MIF were applied to C8 Sep-Pak
cartridges (Waters Associates) and MIF was eluted with 60%
acetonitrile/water, lyophilized, and renaturated. The LPS con-
tent was quantified using the chromogenic Limulus amoebo-
cyte assay.
MIF mutants (C56S, C80S, and N110C) were expressed and
purified as described for the wild type human MIF. C59S and
C56S/C59S mutants were expressed and purified as previously
described by Kleemann et al. (46). Uniformly 15N-labeled pro-
tein samples were prepared for NMR experiments by culturing
the bacteria in M9 minimal medium containing 15N-ammo-
nium chloride (1 g/liter) as the only nitrogen source.
Assay Design to Screen for Potential Inhibitors of MIF
Tautomerase Activity
The assay principle is based on measuring the absorbance of
D-dopachrome methyl ester (red), which is transformed by
enzymatically active MIF to the enol form that is colorless (Fig.
1). In the absence of MIF, the keto form of the substrate shows
an absorbance at 475 nm that diminishes upon addition ofMIF
(supplemental Fig. S1). Keto-enol tautomeric conversion of
D-dopachrome methyl ester by MIF was optimized in cuvette
format as described previously (23). A fresh stock solution of
D-dopachromemethyl ester was prepared through oxidation of
L-3,4-dihydroxy phenylalaninemethyl ester with sodiummeta-
periodate. L-3,4-Dihydroxy-phenylalanine methyl ester (4 mM)
was first diluted in 5 ml of distilled water, then the appropriate
amount of sodium metaperiodate was added to a final concen-
tration of 8mM. The solution wasmixed, incubated for 5min at
room temperature, protected from light and then kept on ice.
D-Dopachromemethyl ester stability over timewas evaluated at
different temperatures. Complete stability was only observed
when the substrate was stored at 4 °C. However, a decrease in
absorbance was easily noticed at room temperature or 37 °C
(supplemental Fig. 1A).
The tautomerase enzymatic activity was measured in 50 mM
potassium phosphate buffer, 0.5 mM EDTA, pH 6.5. MIF (100
nM) dialyzed in 1 PBS was added to the cuvette and the
decrease in absorbance at 475 nm was followed for 3 min using
a CARY 100 Bio UV-visible spectrophotometer. To perform
this assay in an HTS format, MIF (500 nM, 6 l) was added to
384-well plates (Nunc, Black wall, clear bottom) containing 50
mM potassium phosphate buffer, 0.5 mM EDTA, pH 6, and the
compounds of interest at a final concentration of 10 M. MIF
and compounds were mixed and incubated for a fixed time
period of 15 min at room temperature before initiating the
reaction by addition of a fresh stock solution of D-dopachrome
methyl ester, which was prepared as described above (final
reaction volume  80 l). The plates were centrifuged for 2
min at 2000  g to remove air bubbles and the absorbance
was measured at 475 nm using a Saphire II Tecan reader
(supplemental Fig. S2A). As a pos-
itive control, we initially used
ISO-1 and later switched to
ebselen (10 M), which gave com-
plete inhibition of the enzymatic
activity of MIF. The entire assay
was performed using the Biomek 3000 Laboratory Automa-
tion Work station from Beckman Coulter, and the entire
procedure was carried out in the dark. All assays were carried
out in duplicate and hit compounds were retested individu-
ally to eliminate any false positives.
Data Analysis
The Z value was calculated according to the method devel-
oped by Zhang et al. (47),
Z  1 
3 S.D. positive control 3 S.D. negative control
mean positive controlmean negative control)
(Eq. 1)
where S.D. positive control is the standard deviation (n 16) of
the positive control (with 10 M ebselen), S.D. negative control
is the standard deviation (n 24) of the negative control (MIF
in the absence of inhibitor), mean positive control is the mean
(n  16) of the positive control (with 10 M ebselen), and the
mean of the negative control is the mean (n 24) of the nega-
tive control (MIF in the absence of inhibitor).
IC50 and Ki,app Assessment
For the determination of IC50 values, the D-dopachrome was
used as a substrate; the hit compounds were distributed in 384-
well plate at 12 dilutions starting from 0 to 50 M. One percent
DMSOwas used as a final concentration in the reaction buffer;
the assay was performed in triplicate as described above and
each sample was evaluated in duplicate.
Ki,app values were obtained by plotting the relative initial
velocities as a function of the inhibitor concentration. MIF was
preincubatedwith 12 concentrations of hit compounds ranging
from 0 to 50 M for 15 min, followed by the addition of 2 mM
HPP and the absorbance at 300 nm was measured for 3 min.
Data were fitted to the simple inhibition expression using Sig-
maplot software: Vi  (V0/(1  (I/Ki,app)n)) bkg; where V0,
velocity at [I] 0 and n is the Hill coefficient (48). The percent
of inhibition was calculated relative to the DMSO vehicle
control and blank control as: % inhibition  100  (100 
(test compound value  average of blank control)/(average of
DMSO control average of blank control)).
MALDI-TOFMSMeasurements to Examine Possible Protein
Modifications
Matrix-assisted laser desorption ionization-time of flight
mass spectrometry (MALDI-TOFMS)was performed to exam-
ine any inhibitor-induced protein modifications. The matrix
solution was prepared by dissolving 14 mg/ml of sinapinic acid
solution in 0.1% trifluoroacetic acid/acetonitrile (1:1). A thin
matrix layer was generated on the mirror-polished target using
a gel loading tip. One microliter of sample (15 M MIF incu-
batedwith 10Mhit compounds for 1 h) wasmixedwith 1l of
FIGURE 1.MIF catalyzed tautomerization of D-dopachrome.
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sinapinic acid matrix solution, and 0.8 l of this mixture was
deposited on top of the thin layer and allowed to air dry. The
samples were analyzed with a 4700 MALDI-TOF/TOF instru-
ment (Applied Biosystems).
Protein DigestionMass Spectrometry Analysis to Identify the
Modified Residue(s)
Twenty microliters of MIF sample previously incubated for
1 h with inhibitors at 10 M were digested overnight with tryp-
sin, 1:50 (Promega). The digestionwas stoppedwith 1l of 10%
formic acid and stored at 4 °C until further use. The samples
were analyzed by MALDI-MS on a 4700 MALDI-TOF/TOF
instrument (Applied Biosystems) or an Axima CFR plus instru-
ment (Shimadzu) without further purification. One microliter
of sample wasmixedwith 1l of 2,5-dihydroxybenzoic acid (20
mg/ml in 1% phosphoric acid/acetonitrile (1:1)), and 0.8l of this
mixture was deposited on the target and allowed to air dry.
Probing the Effects of the Hit Compounds onMIF
Oligomerization by Analytical Ultracentrifugation
Analytical ultracentrifugation experiments were performed
using purified and dialyzed MIF samples (10 M) preincubated
with ebselen for 1 h at an inhibitor concentration correspond-
ing to 100% inhibition. Radial UV scans were recorded on a
BeckmanOptima XL-A at a wavelength of 277 nm. Sedimenta-
tion velocity experiments were carried out at 20 °C using 380–
400 l of protein solution. Data were recorded at rotor speeds
of 50,000 rpm in continuousmode, with a step size of 0.003 cm.
The experimentally determined partial specific volume of 0.765
ml/mg was used to calculate the molecular weight of wild-type
MIF (49). The sedimentation velocity profiles were analyzed as
a c(s) distribution of the Lamm equation using SEDFIT (50). To
obtain the molecular weights, molar mass distributions c(M)
were obtained by transforming the corresponding c(s) using
SEDFIT.
MIF Aggregation Studies
Wild type humanMIF at a concentration of 15M in 1 PBS
was incubated with different ebselen concentrations ranging
from0.01 to 1mM for 1 h at room temperature, and then filtered
with a 0.2-m filter (Millipore). The retentate was solubilized
in 0.1% SDS. Both the supernatant and the resolubilized aggre-
gates were analyzed in a 15% SDS gel. To further examine cys-
teine-induced aggregation by ebselen, either the N110C stable
cross-linked trimer or the alkylated wild type human MIF or
cysteine mutants were tested.
Cysteine Alkylation
To determine whether some of the hit compounds induce
their effect via modification of cysteine residues (i.e. Cys56,
Cys59, and Cys80), all free thiols were blocked by covalent mod-
ification withmaleimide (3,3-N-[e-maleimidocaproic acid)hy-
drazide, trifluoroacetic acid salt (EMCH)) (Pierce). Fifteen
micromolar wild type or mutant forms of human MIF in 1
PBS, pH 7.4, was incubated with 10 mM EMCH for 1 h at room
temperature. The unreacted EMCH was removed using PD-10
desalting columns (Pierce). The collected fractions were ana-
lyzed in an SDS-PAGE gel and the concentration was assessed
using a UV spectrophotometer.
NuclearMagnetic Resonance (NMR) Spectroscopy
NMR spectra were acquired at 27 °C on a Bruker Avance III
600 MHz NMR spectrometer. 500 M wild type human MIF
samples were prepared in 20 mM Na2HP04, 0.5 mM EDTA,
0.02% NaN3, pH 7.0, and 10% D2O. A specific amount of each
compound was prepared in DMSO and mixed with the above
sample to give a final 1%DMSO concentration in the total sam-
ple volume. Two-dimensional 1H-15N heteronuclear single
quantum coherence (HSQC) spectra were recorded using 48
scans per increment with 256 1024 complex data points in F1
and F2 dimensions and relaxation delay of 1.0 s. Spectra were
processed with Topspin (Bruker Biospin, Germany) and
NMRPipe (51). Visualization and manipulation was performed
using Sparky 3.110.3 Averaged chemical shift deviation was cal-
culated with Equation 2.
dN5  2  dH2 (Eq. 2)
Biological Assays
Glucocorticoid Overriding Assay—Mouse RAW 264.7
macrophages (TIB-71, ATCC) were grown in RPMI 1640
medium containing 2 mM glutamine and 10% fetal calf serum.
MIF was incubated with the inhibitors for 15 min at room tem-
perature. RAW 264.7 macrophages (5  104 cells/well in
96-well plates) were preincubated for 1 h with 107 M dexa-
methasone, dexamethasone plus murine MIF (100 ng/ml; 8
nM), or dexamethasone plus MIF and Hit compounds at 10 M
before the addition of 100 ng/ml of SalmonellaminnesotaUltra
Pure LPS (List Biologicals Laboratories). TNF in cell culture
supernatants collected after 4–8 h was measured by enzyme-
linked immunosorbent assay (BD Biosciences).
Phosphorylation of AKT by MIF—Confluent HeLa cells
(CCL-2) were grown in Dulbecco’s modified Eagle’s medium
containing 10% fetal calf serum. Cells were incubated for 2 h
with human MIF (50 ng/ml; 4 nM) in the presence of hit com-
pounds at final concentrations of 1 and 10M. Phosphorylation
of AKT at Ser473 wasmeasured using the Alpha screen SureFire
phosphokinase kit, according to the protocol provided by the
manufacturer (PerkinElmer Life Sciences) (53).
MIF-triggered Chemotaxis Assay—Chemotactic assays were
performed with primary human endothelial progenitor cells
(EPCs). EPCs were isolated from the mononuclear cell fraction
obtained by density gradient centrifugation from human blood
essentially as previously described (54). Briefly, “buffy coats”
were obtained from volunteers in accordance with the local
ethics committee. CD34 cells were enriched from mononu-
clear cells by Biocoll density gradient centrifugation andCD34-
specific magnetic separation. CD34 cells were plated on
fibronectin-coated 6-well plates and cultured in endothelial
growth medium (MV2). Endothelial progenitor cells were har-
vested on day 14 and their identity verified by fluorescence-
3 T. D. Goddard andD. G. Kneller (2010) SPARKY 3, University of California, San
Francisco, CA.
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activated cell sorter analysis to stain for lectin-fluorescein iso-
thiocyanate, DiI-conjugated acLDL, CD31, and VEGFR-2 (KDR)
at a rate of 	90%. EPC chemotaxis was evaluated using Tran-
swell cell migration chambers in combination with FluoroBlok
inserts (BD Biosciences; 8-m pore size) in a 24-well plate for-
mat. Lower chambers contained 10 ng/ml of recombinant
human MIF or (100 ng/ml; 0.8 nM) LPS in medium containing
0.5% bovine serum albumin as the chemoattractant. Calcein-
stained (Calbiochem) EPCs were preincubated with 10 M
compound and placed into the upper chambers (50,000 cells
per insert). Fluorescence signals representing the migration of
calcein-stained cells into the bottom chambers were deter-
mined 3 h later using a fluorescence microplate reader. As day
14 EPCs express CD14, LPS (100 ng/ml) was used as a positive
control. The percentage of cells migrated to the lower chamber
was determined after 3 h.
Compound Toxicity Studies Using MTT Assay—RAW 264.7
macrophages (5  104 cells/well in 96-well plates) were incu-
bated with 3, 10, and 20 M of each compound. Twenty-four
hours later, toxicity was assessed using theMTT assay (Sigma).
Absorbance was recorded at 405 nmwith 590 nm as a reference
wavelength.
RESULTS
High Throughput Screening Identifies 18 Novel Inhibitors of
MIF Tautomerase Activity
The tautomerase assay is a well established method to assess
MIF-specific enzymatic activity, and has yielded reproducible
results in different laboratories (22, 23, 55). We optimized the
conditions for performing this assay in a high throughput (384-
well plates) format. Two known non-physiological MIF sub-
strates (D-dopachrome and phenylpyruvate) were evaluated.
D-Dopachrome was chosen for screening because it absorbs at
475 nm, a wavelength at which small molecules do not absorb,
which is not the case forHPP (300nm).As a positive control, we
initially used ISO-1, a known inhibitor of the enzymatic activity
of MIF (35). A validation assay was performed to test the
screening conditions in an automated manner and determine
the robustness and reproducibility of the assay. Intra-plate and
inter-plate variations were determined using single point mea-
surements and Z values of 0.74 and 0.91 were obtained.
An FDA-approved library (NINDS Custom Collection II)
composed of 1,040 bioactive compounds containing a diverse
set of drugs, 85% ofwhich aremarketed drugswith awide range
of therapeutic usage including anti-inflammatory and analge-
sia, and theMaybridge library composed of 14,400 compounds
were screened. The compounds were dissolved in DMSO to
yield a final concentration of 10 M. DMSO alone at a final
concentration of up to 2% had no effect on MIF tautomerase
activity (supplemental Fig. S1B). The inhibitor screening assay
was performed as follows: MIF was added to 384-well plates
containing the compounds in reaction buffer and incubated for
15 min at room temperature. The enzymatic reaction was ini-
tiated by adding the D-dopachrome substrate. In the positive
control wells, with no enzyme, or with compounds only, the
absorbance of the substrate at 475 nm was
0.9–1, whereas in
the presence of enzyme the absorbance rapidly decreased (
3
min) to an OD value of 
0.1 (supplemental Fig. S2A). In our
preliminary screens, ebselen was identified as a potent inhibi-
tor, which fully inhibited MIF tautomerase activity at a con-
centration of 10 M, making it more effective than ISO-1.
Thus, ebselen was used as a positive control (10 M) in all
subsequent screens. The Z value for the FDA and May-
bridge library screenings were 0.74 and 0.91, respectively
(supplemental Fig. S2B). These data suggested that the assay
is quite robust and reproducible. The hit compounds dem-
onstrating greater than 50% inhibition of MIF activity were
retested manually to exclude false positives. Of the 15,440
compounds tested, only 18 were found to be active (Fig. 2
and Table 1) and demonstrated more than 70% inhibition in
the primary assay. To determine the IC50 values, we per-
formed concentration-dependent studies by testing 12 dif-
ferent dilutions ranging from 0 to 50 M and obtained IC50
values in the range of 0.2–15.5 M (Fig. 3).
MIF Antagonists: Mode of Action
Inhibition of the tautomerase activity ofMIF can occur via at
least five different mechanisms: 1) binding to the active site; 2)
allosteric inhibition; 3) covalent modification of active site res-
idues; 4) disruption of the active site through compound-in-
duced dissociation of the active trimer; and 5) stabilization of
the MIF monomer and prevention of its re-association to form
the active trimer. The inhibitors identified in our HTS were
subjected to biochemical and biophysical studies to understand
their mechanism of action.
The Compounds 1, 2, 4, 5, 6, 7, 8, 10, 12, 13, and 14 Inhibit MIF
Tautomerase Activity by SelectiveModification of the
Catalytic N-terminal Proline Residue
To determine whether MIF inhibitors covalently modify
MIF, the compounds were incubated for 1 h at room tempera-
ture with 15 M humanMIF (in 25 mM Tris buffer, pH 7.4) and
subjected to analysis by MALDI-TOF mass spectrometry.
Upon incubationwith 10Mof corresponding compounds 1, 2,
4, 5, 6, 7, 8, 10, 12, 13 and 14, we observed a shift in the mono-
meric molecular mass consistent with a single modification of
MIF (supplemental Fig. S3). To identify the site of covalent
modifications, the modified MIF was subjected to proteolytic
digestion by trypsin and peptide mapping by mass spectrome-
try. In the case of compounds 2, 6, 8, and 12, we observed a
peptide fragment with molecular mass corresponding to that
comprising N-terminal residues PMFIVNTNVPR (molecular
mass 1287.6Da) plus onemolecule of inhibitor.MS/MSanal-
yses and sequencing of themodified peptide fragments revealed
that modification by these compounds takes place exclusively
at the N-terminal proline residue.
Dissociation Constant (KD) Reveals a Strong Binding Behavior
for HCLP and Compound 9
No covalent modifications were observed when compounds
3, 9, 11, and HCLP were incubated with MIF, suggesting that
the inhibitory activity of these compounds is mediated by non-
covalent interactions with the protein. To evaluate the strength
of binding, the KD for each compound was measured using
fluorescence spectroscopy. MIF at 5 M was incubated with
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increasing concentrations of compounds and binding was eval-
uated by monitoring changes in the tryptophan emission max-
imum upon MIF binding to compounds. The maximum fluo-
rescence emission was plotted as a function of compound
concentration andnormalized.HCLP and compound9 showed
KD values of 1.5 0.1 and 2.11 0.15 M, respectively. Com-
pounds 3 and 11 exhibitedKD values of 6.28 1.02 and 24.45
6.74 M, respectively (Fig. 4).
Elucidating the Structural Basis Underlying the Inhibitory
Activity of Ebselen, HCLP, and Compounds 3, 9, and 11
Using NMR
Todetermine the structural basis for the inhibition of human
MIF enzymatic activity, NMR titrations were performed with
ebselen, HCLP, and compounds 3, 9, and 11.
Ebselen—Anequimolarmixture ofMIFwith ebselen resulted
in severe resonance broadening throughout the whole se-
quence, indicative of conformational exchange (Fig. 5A). Most
drastic effects were seen for residues 3–5, 38–39, 49–51,
61–62, 64, 99, 101, 106–108, and 112. Most of these residues
are in the subunit-subunit interface. The -sheet core of a
monomeric subunit that consists of four -strands, as well as
the three -strands coming from the other two subunits are
highly affected by ebselen (Fig. 5, B and C), which supports the
idea that a stable trimer dissociates intomonomeric units upon
destabilization by ebselen. In agreement with the sedimenta-
tion velocity experiments (see below), the drop in signal inten-
sity could be due to a combination of both conformational
changes and aggregation of the dissociated monomeric sub-
units into larger moieties that are beyond the detection limit of
liquid stateNMR.Among the three cysteines ofMIF, onlyCys59
displays a minor chemical shift, such an effect is observed for
neither Cys56 nor Cys80 (supplemental Fig. S4A). Additionally,
the only residue that has surface accessibility is Cys59
(supplemental Fig. S4, B-D), suggesting a role for this residue in
ebselen interaction. No change is observed for the -helices.
HCLP—Titration of MIF with HCLP results in both reso-
nance broadening and chemical shift changes (Fig. 6A), indica-
tive of an intermediate exchange regime in theNMR time scale.
The residues that are most affected by HCLP are 3–5, 35–38,
64, 67, 95, 107–110, 112, and 114 (Fig. 6B). Similar to the MIF
inhibitor benzyl isothiocyanate (56) and HPP (31), these resi-
dues cluster aroundPro1. Among these residues, Ile64 andTyr95
are found in the active site.
Compounds 3, 9, and 11—Backbone amide signals of MIF
were monitored for hit compounds 3, 9, and 11. An equimolar
mixture of MIF and compound 3 resulted in chemical shift
deviations averaged on 1H and 15N dimensions in residues 2–3,
35–39, 49–51, 63–66, 94–96, 107–110, and 112–113 (Fig. 6, A
and B). Many of these residues are located in the subunit-sub-
unit interface and enzymatic active site (Fig. 6C). Upon addition
of compound 9, more than 0.75 molar ratio relative to MIF,
several peaks in the HSQC analysis disappeared, indicating
FIGURE 2.High throughput screening of theNINDS andMaybridge libraries resulted in the identification of 18 novel inhibitors.Chemical structures of
the primary and validated hits.
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TABLE 1
Summary table of Maybridge hit compounds code, name, structure, IC50, Ki,app and the mass shift observed bymass spectrometry upon
30min incubation with MIF covalent modifiers
MIF Inhibition
AUGUST 20, 2010•VOLUME 285•NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 26587
 at EPFL Scientific Inform
ation and Libraries, on Novem
ber 10, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
intermediate exchange of conformation. These peaks reap-
peared with an increasing molar ratio of compound 9, which
implies a higher affinity of this inhibitor to MIF. Addition of
compound 9 toMIF also induced a chemical shift deviation, but
with two sequential changes: first a milder interaction followed
by conformational changes in MIF. Up to a 0.5 molar ratio of
compound 9, resonances from residues 2–3, 35–37, 50, 58, 60,
61, 65–66, 75, 81, 93, 95–96, 98, 107–108, and 110–111, which
correspond to the subunit-subunit interface and enzymatic
active site were observed (Fig. 6, B andC). Although compound
11 had the lowest IC50 value in the MIF tautomerase assay, its
binding to MIF resulted in an even larger number of residues
affected by slow conformational exchange, including residues
2–3, 35–37, 58–60, 60, 65–68, 72–78, 97–102, 105–106, and
112–114 (Fig. 6B). The residue stretches affected by slow con-
formational exchange are located in the subunit-subunit inter-
face and close to the active site (Fig. 6C).
Structure-Activity Relationship Studies for Hexachlorophene
Hexachlorophene did not lead to covalent modification of
MIF. Fortunately, several analogues of HCLP are commercially
available. Therefore, we performed structure-activity relation-
ship studies to better understand its mechanism of action and
to identify the chemical groups responsible for evoking tau-
tomerase inhibition. Eleven analogues of HCLP (Fig. 7A) were
selected and tested. Only MDPI894 (IC50, 8 M), bithionol
(IC50, 6.5 M and Ki,app, 4.74  0.85 M), and dichlorophene
(IC50, 15 M and Ki,app, 6.57  0.54 M) were observed to
exhibit significant inhibition ofMIF comparedwithHCLPwith
IC50, 3.5M, andKi,app, 2.21 0.39M (Fig. 7B). Compound 5,
bis(2-hydroxyphenyl)methane, which lacks any of the chlorine
substitutions in the phenol rings is inactive. Interestingly, the
addition of only two chlorine atoms at the 3,3 positions,
dichlorophene, was sufficient to transform this molecule into
an active inhibitor of MIF, albeit less active than HCLP.
Removal of either the hydroxyl groups or the 3,3 chlorine
atoms results in loss of HCLP inhibitory activity. Together, the
FIGURE 3. Ki,app obtained by plotting relative initial velocities as a function of inhibitor concentration and data fitting to the simple inhibition
expression:Vi (V0/(1 (I/Ki,app)
n))bkg,whereV0, velocity at [I] 0, and n theHill coefficient. Each data point represents themean S.D., n 4. The
data were analyzed using Sigma plot software and each experiment was done in triplicate.
FIGURE 4. Dissociation constant (KD) measurements for HCLP and com-
pounds 3, 9, and 11 determined by monitoring MIF tryptophan fluores-
cence quenching at 295 nm as a function of increasing concentration of
MIF inhibitors.
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structure activity results shown in Fig. 7 highlight the impor-
tance of the 6,6 hydroxyl groups and 3,3 chloride atoms for
MIF inhibition. Furthermore, our results suggest that the
position of the remaining chlorine atoms on the aromatic
rings as well as the nature of the bridging atom influence the
potency of HCLP. The inhibitory activity of bithionol dem-
onstrates that replacing the bridging carbon atom of HCLP
by a sulfur and removal of the chlorine atoms at the 2,2
positions reduce the inhibitory potency of HCLP. Substitu-
tion of the bridging carbon by a sulfoxide results in loss of
inhibitory activity despite the presence of the chlorine atoms
at the 3,3, and 5,5 positions, suggesting that some confor-
mational flexibility between the two phenol rings is crucial to
allow these inhibitors to adopt the right conformation in the
active site.
Sedimentation Velocity Demonstrates That Only Ebselen
Induces Trimer toMonomer Dissociation
To determine whether any of the antagonists functioned by
disrupting the MIF trimer, we compared the quaternary struc-
ture distribution of human MIF in the presence or absence of
inhibitors by sedimentation velocity analytical ultracentrifuga-
tion. Human MIF preincubated with DMSO as a control sedi-
mented predominantly as a single species with a sedimentation
coefficient and molecular mass corresponding to that of the
trimer (s 3.15 0.1 S and 36,373 kDa) (Fig. 8A). In the pres-
ence of ebselen, at a concentration corresponding to the IC50 (3
M, Fig. 8A), we observed an addi-
tional sedimenting species with an
average s value of 1.7  0.2 S and a
molecular mass of 12,428 kDa,
indicative of the presence of mono-
meric MIF (Fig. 8B). Studies at
higher ebselen concentrations were
not possible due to ebselen-induced
aggregation and precipitation of
MIF (Fig. 9A). None of the other
inhibitors was shown to disrupt the
MIF trimer.
Ebselen Inhibits MIF Tautomerase
Activity by Inducing Cysteine-
mediatedModification, Trimer
Dissociation, and Aggregation
ofMIF
Ebselen is a well known anti-in-
flammatory and antioxidant drug
(57, 58). The therapeutic effects of
ebselen have been linked to its per-
oxidase activity; it has high chem-
ical reactivity toward hydroperox-
ides and thiols. Ebselen has been
used as a probe for characterizing
cysteine-targeted oxidation of thi-
oredoxin (59). In bovine systems,
free ebselen quickly reacts with
thiols to form two metabolites, an
ebselen-glutathione adduct and an
ebselen-cysteine adduct (60). MIF monomer has three cys-
teine residues at positions 56, 59, and 80. Previous studies
showed that mutating or alkylating the cysteine residues at
positions 56 or 59 led to a reduced conformational stability
of MIF (61).
To determine whether ebselen inhibition of MIF is medi-
ated by covalent modification of specific cysteine residues,
mass spectrometry analyses were carried out on MIF sam-
ples preincubated with increasing concentrations of ebselen
(0–10 M) for 1 h at room temperature. MALDI-TOF anal-
ysis revealed a peak with a m/z  12620.48, which corre-
sponds to monomeric MIF with one bound molecule of
ebselen (molecular mass of 274 Da). However, we also
observed that ebselen induced rapid aggregation and precip-
itation of MIF. To quantify the degree of ebselen-induced
MIF aggregation, the samples were centrifuged at high speed
(13,000 g) and the supernatants and pellets were collected
and analyzed in SDS-PAGE gels. Fig. 9A demonstrates that
the amount of MIF remaining in solution decreased as the
concentration of ebselen increased, with complete precipi-
tation of MIF at ebselen concentrations of 15 M.
Blocking Cysteine Residues by Alkylation or Chemical
Cross-linking Prevents Ebselen-inducedMIF Aggregation
MIF contains three free cysteines at positions 56, 59, and 80.
To assess whether ebselen-induced aggregation is mediated via
covalent modification of specific cysteine residue(s), wild-type,
FIGURE 5. Structural basis for the inhibition of MIF enzymatic activity by ebselen using NMR. A, the
two-dimensional 1H-15NHSQC reference spectrum (black) was recordedwithMIF in the presence of 1%DMSO.
The addition of ebselen to MIF at equimolar concentrations (red spectra) resulted in resonance broadening.
B, changes in NMR signal intensities in a 1H-15N HSQC upon addition of ebselen. C and D, residues with peak
intensity ratios below 0.18 in B are highlighted in red on the three-dimensional structure of MIF (PDB code
1GD0). C andD are related to each other by 90°. Cyan, green, and pink show the three different subunits of MIF.
The catalytically active P1 residue is indicated in yellow.
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C56S, andC59SMIFwere expressed, purified, and alkylated for
1 h at room temperature using 10 mMmaleimide. In the case of
wild-type MIF, a major peak of 13,020 Da, corresponding to
monomeric MIF with three alkylated cysteine residues (molec-
ular mass of maleimide is 225.4 Da) could be detected by MS,
confirming total alkylation of MIF under the native conditions
(Fig. 9B). After removal of excessmaleimide, alkylatedMIF was
incubated for 1 h at room temperaturewith 100M ebselen and
the sample mixtures were centrifuged at 13,000 g for 15 min.
The supernatant and the re-suspended pellet (in the original
working volume) were then analyzed in a 15% SDS gel to quan-
tify the amount of soluble and precipitated protein. As
expected, no aggregation could be observed for the alkylated
wild typeMIF, and likewise not for the C59S and C56S cysteine
mutants (Fig. 9C), whereas the non-alkylated forms of all three
proteins underwent complete aggregation. The C56S/C59S
double mutant behaved similarly to wild type MIF, indicating
that covalentmodification through Cys80 is sufficient to induce
the aggregation and precipitation of MIF. To verify that
ebselen reacts with cysteine 80, both wild-type and the C80S
MIF mutant were incubated separately with ebselen and the
samples were analyzed by MALDI-TOF mass spectrometry
(supplemental Fig. S5). Addition of ebselen resulted in a
mass shift corresponding to the addition of a single molecule
of ebselen to the wild type protein. A minor peak with anm/z
of 12,894.19 Da corresponding to the addition of two mole-
cules of ebselen was also observed. Upon tryrptic digestion,
we observed a mass shift by 274 Da in a peptide fragment
comprising residues 78–86 (78LLCGLLAER86) in the
case of wild type MIF but not the C80S mutant
(supplemental Fig. S5). This observation combined with the
MS/MS fragmentation patterns (data not shown) suggest
that ebselen modification of MIF occurs at cysteine 80.
Although our mass spectrometery data demonstrated that
ebselen modifies MIF at multiple cysteine residues (sup-
plemental Fig. S5), our peptide coverage did not allow us to
FIGURE 6. Structural basis for the inhibition of MIF enzymatic activity by compounds 3, 9, and 11 using NMR. A, the two-dimensional 1H-15N HSQC
reference spectrum of MIF (black) was recorded in the presence of 1% DMSO. Addition of the three hit compounds to MIF at equimolar concentrations (red)
resulted in NMR chemical shift changes and signal broadening. In case of compounds 9 and 11, a set of new NMR resonances appeared at equimolar ratio.
Titration data of HCLP are given for comparison. B, averaged 1H-15N chemical shift deviation observed for backbone resonances of MIF in two-dimensional
1H-15NHSQCNMRspectra uponadditionof compounds3,9,11, andHCLPat equimolar ratio (shown inA). Residues affectedby slowconformational exchange
are indicated by gray bars. C, residueswith averaged 1H-15N chemical shift changes above 0.02 ppmare highlighted on the three-dimensional structure ofMIF
(PDB code 1GD0) using a stick model representation. Cyan, yellow, and pink depict the different subunits of MIF.
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detect peptide fragments compris-
ing the other cysteine residue,
Cys56 and Cys59. Therefore, we
were not able to determine more
precisely the extent of modifica-
tion at each of these residues.
Ebselen-induced Aggregation of
MIF Is Mediated by Disruption of
the Trimer
Based on our experience, theMIF
trimer is very stable, whereas the
monomer is extremely unstable and
undergoes rapid aggregation upon
dissociation from the trimer.
Attempts to populate the monomer
using inter-subunit disruption muta-
tions and chemical agents were
unsuccessful in destabilizing the tri-
mer or led to the expression of (pre-
sumably monomeric) MIF in inclu-
FIGURE 7. Structure-activity relationship studies for hexachlorophene. Chemical structures of selected HCLP analogues that were tested in the tautomer-
ase assay. A, 1, HCLP; 2, MDPI894; 3, dichlorophene; 4, bithionol; 5, bis(2-hydroxyphenyl)methane; 6, 2,2-diaminodiphenyl sulfide; 7, 2,2-sulfinyl-bis(4,6-
dichlorophenol); 8, irgasan; 9, 4,4-dichlorobenzophenone; 10, 3,4-dihydroxybenzophenone; 11, benzophenone; 12, emodin. B, Ki,app of HCLP, bithionol, and
dichlorophene.
FIGURE 8. A, IC50 determination of ebselen using D-dopachrome methyl ester as a substrate. Every data point
represents an average of four replicates. B, sedimentation velocity profiles of wild-type (Wt) humanMIF in the
presence or absence of ebselen. 10 M MIF in 1 PBS was preincubated with 3 M ebselen for 1 h at room
temperature. Sedimentation coefficient distributions were obtained by analysis of the sedimentation profiles
using the C(s) distribution as a variant of Lammequation solutions. Calculations were performed using SEDFIT
software (50).
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sion bodies.4 These findings are consistent with the absence of
any reports in the literature demonstrating the accumulation
of monomeric MIF or existence of stable monomeric MIF
mutants. In our hands, the presence ofmonomer is always asso-
ciated with accumulation of higher molecular weight aggre-
gates of MIF (43). These findings suggest that ebselen-induced
aggregation could be mediated by the induction of trimer-to-
monomer dissociation and subsequent aggregation of the
unstable monomeric species (Fig. 10). To test this hypothesis
further, we designed and produced a disulfide-linked MIF
mutant, which forms a stable trimer upon oxidation. This
mutant was generated by replacing the C-terminal residue
asparagine 110 with cysteine (N110C) to form an intermo-
lecular disulfide bond between Cys110 and Cys80 at the mon-
omer-monomer interfaces of the trimer (Fig. 10A). N110C
undergoes spontaneous oxidation to form inter-subunit dis-
ulfides resulting in the formation of a stable cross-linked
MIF trimers as the predominant species in solution under
physiological conditions. Interestingly, co-incubation of the
disulfide-linked N110C MIF trimer with increasing concen-
trations of ebselen had no effect on trimer stability. We
did not observe any MIF aggrega-
tion even after longer incubations
(Figs. 9D and 10B). The MIF band
intensity of the control sample
(N110C only) was equivalent to
the bands corresponding to sam-
ples preincubated with various
ebselen concentrations (Fig. 10B),
suggesting that trimer stabiliza-
tion via disulfide formation in-
volving Cys80 prevents ebselen-in-
duced MIF dissociation and
aggregation.
MIF Tautomerase Inhibitors Display
Low Toxicity on RAW264.7
Macrophages
The relative cytotoxicity of the
investigated tautomerase inhibitors
of MIF was analyzed by incubating
RAW 264.7 macrophages for 24 h
with 3, 10, and 20 M of the various
compounds. The toxicity was then
evaluated using the MTT assay. A
very low cytotoxicity was seen with
all inhibitors at 3 and 10 M, except
for benzyl isothiocyanate and inhib-
itors 2 and 8 at 10 M that resulted
in 
25% cytotoxicity. At 20 M,
MIF inhibitors 12, 13, and 15 and
HCLP showed an increased toxicity
to 30–40% (supplemental Fig. S7).
Further studies are required to
determine whether the increase in
MTT toxicity by these compounds
is mediated by blocking MIF, which is known to be
anti-apoptotic.
MIF Tautomerase Inhibitors Significantly Inhibit MIF-mediated
Overriding of Glucocorticoid Activity
An important feature of the biology of MIF is its ability to
override the immunosuppressive effects of glucocorticoids on
proinflammatory cytokine production (62, 63). Therefore, we
examinedwhether theMIF tautomerase inhibitors identified in
this study interfered with the immunoregulatory function of
MIF on RAW 264.7 macrophages. RAW 264.7 macrophages
were preincubated for 1 hwith dexamethasone (100 nM)with or
without recombinant MIF (100 ng/ml; 8 nM) and ebselen,
HCLP, and the HCLP analogues bithionol, MDPI894, and
dichlorophene as well as the inhibitors 1, 2, 3, 4, 5, 9, and 11 (all
used at 10 M) prior to stimulation with LPS (100 ng/ml). TNF
production was quantified in cell culture supernatants col-
lected 4 h after stimulation. Treatment of RAW264.7 cells with
MIF overcame dexamethasone inhibition of TNF production.
Ebselen, HCLP, bithionol, and MDPI894, but not dichloro-
phene, fully inhibited the capacity ofMIF to override the immu-
nosuppressive effect of dexamethasone on LPS-induced TNF
production (Fig. 11A). Dichlorophene only slightly (25%) inhib-4 F. El-Turk and H. A. Lashuel, unpublished results.
FIGURE 9. Ebselen induces MIF aggregation via interaction with cysteine. A, wild-type human MIF
dialyzed against 1 PBS incubated with different ebselen concentrations (0, 1, 10, 100, and 1000 M) for
120min and filtered with a 0.2-m filter by centrifugation at 13,000 g for 5 min; both the filtrate and the
retentate, which were resolubilized in 1% SDS, were analyzed in a 15% SDS gel. B, MALDI-TOF spectrum
demonstrating that the three cysteine residues of MIF were alkylated upon co-incubation with 10 mM
maleimide for 1 h. C, ebselen induces the aggregation of only non-alkylated forms of wild type (WT), C56S,
and C80S MIF. Cystein alkylation of each protein abolishes ebselen-induced aggregation of MIF. Ten
micromolar wild type, C56S, and C80S MIF were alkylated with 10 mM maleimide. The alkylated and the
non-alkylated proteins were incubated with 0, 5, 10, 50, and 100 M ebselen for 1 h at room temperature
and centrifuged for 15 min at 13,000 g, and the supernatant were analyzed in a 15% SDS gel by Western
blot using the anti-MIF antibody (Zymed Laboratories Inc. at 1:20,000). D, comparison of aggregation
propensity as determined by quantification of the band intensity of remaining soluble MIF (wild-type,
C80S, C56S, and N110C) as a function of ebselen concentration.
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ited MIF overriding capacity, in line with the concept that the
catalytic site of MIF is important for MIF counter-regulatory
activity and that dichlorophene was a less potent inhibitor of
MIF tautomerase activity compared with ebselen, HCLP,
bithionol, and MDPI894. Bithionol and MDPI894 seemed to
revert the MIF effect below the level of dexamethasone LPS,
which could be attributed to their ability to inhibit endogenous
MIF as well. Similarly, inhibitors 1, 2, 3, 4, 5, 9, and 11 abro-
gated the MIF-mediated dexamethasone overriding activity
(Fig. 11B). Taken together, these results demonstrate that com-
pounds that inhibitMIF tautomerase activitywere also efficient
in inhibiting the overriding activity of MIF on glucocorticoids,
suggesting that these two activities are linked.
Ebselen and HCLP Inhibit MIF-mediated AKT Phosphorylation
Previous studies have shown that MIF has anti-apoptotic
activity and that it promotes tumor cell survival through acti-
vation of the AKT pathway (64). Exogenously added recombi-
nantMIF led to an enhancement of phosphoinositide 3-kinase-
dependent AKT phosphorylation in NIH3T3 and HeLa cells
(64). To probe the effect of ebselen and HCLP on MIF-medi-
atedAKTphosphorylation,wequantifiedthelevelofphosphory-
lated AKT in HeLa cells incubated for 2 h with or without MIF
(50 ng/ml) in the presence or absence of 1, 10, and 100 MMIF
inhibitors, or DMSO as a control. The level of phosphorylated
AKT was quantified using the Alpha screen technology. As
shown in Fig. 12, MIF increased the level of phosphorylated
AKT by 1.5-fold in HeLa cells, an effect that was fully inhibited
by ebselen and HCLP and the control phosphoinositide 3-ki-
nase inhibitor LY294002. Of note, ebselen, HCLP, and
LY294002 dose-dependently decreased phosphorylated AKT
levels above control values, whichmay suggest that endogenous
MIF plays a role in sustaining AKT phosphorylation in resting
HeLa cells.
EbselenModulatesMIF-triggered Chemotactic Migration
Responses
MIF has been found to promote monocyte chemotactic
migration through activation of its receptor CXCR2 (54, 65).
The oligomeric MIF species responsible for this effect is still
unknown. More recently, MIF has also been shown to potently
enhance the chemotactic migration of EPCs. Day 14-differen-
tiated EPCs representing late outgrowth EPCs express CD14
and thus have both endothelial cell and monocyte-like proper-
ties. EPCs and monocytes play an important role in angio- and
vasculogenic processes and atherogenic inflammation, respec-
FIGURE 10. Ebselen-inducedaggregationofMIF ismediatedbydisruptionof the trimer.A, a ribbondiagramof the interface between twoMIFmonomers
illustrating the positions of Cys80 and Asn110, whichwasmutated to cystine (N110C) to engineer the intersubunit disulfide bridge. The N110C cross-linkedMIF
migrates as a stable trimer in SDS gel, but disassociates into monomer in the presence of 10 mM dithiothreitol. B, N110C cross-linked MIF trimer does not
undergo aggregation upon addition of ebselen up to a concentration of 1 mM. C, schematic depiction illustrating the mechanism of ebselen-induced
aggregation of MIF. Reaction of ebselen with MIF induces conformational changes and trimer disassociation resulting in the population of monomeric MIF,
which is highly prone to aggregation. Cysteine alkylation and/or trimer stabilization via intersubunit disulfide cross-linking prevents ebselen-induced disso-
ciation and aggregation of MIF.
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tively, and MIF has been implicated to play a role in the corre-
sponding EPC and leukocyte recruitment processes. To begin
to address potential effects of the tautomerase inhibitors on
these inflammatory and angiogenic activities of MIF, MIF-me-
diatedEPCchemotaxiswas studied in the presence and absence
of a selection of the compounds. Recombinant MIF or LPS as a
control were added to the lower chamber of a Transwell device,
whereas EPCs and compounds were added to the upper cham-
ber. Directed chemotactic migration was followed over a time
interval of 3 h. MIF led to a 1.53-fold enhancement of the che-
motactic index. Inhibitors alone did not affect EPC chemotaxis.
Surprisingly, ebselen pretreatment of EPCs markedly and sig-
nificantly promoted migration of EPCs (chemotactic index 
2.8). Thus, ebselen exhibited a hyperagonistic effect. HCLP
acted in a hyper-agonisticmanner as well, but this effect did not
reach statistical significance. The MIF inhibitors 1, 2, 3, 4, 5,
and 9neither inhibited nor enhancedMIF-directed EPCmigra-
tion (Fig. 13).
DISCUSSION
Given the role of the quaternary structure and the C-termi-
nal region in modulating the catalytic activity of MIF, we can
envision several mechanisms by which small molecules could
inactivate MIF tautomerase activity: 1) binding to the active
site; 2) allosteric inhibition; 3) covalent modification of active
site residues; 4) disruption of the active site through com-
pound-induced dissociation of the tautomerase-active trimer;
and 5) stabilization of the MIF monomer and prevention of its
re-association to form the active trimer. However, current
efforts aimed at developing small molecule inhibitors of MIF
are focused primarily on rational structure-based design
approaches targeting the active site. Although these efforts
have resulted in the discovery of several classes of active site
inhibitors of MIF and have advanced our knowledge regarding
the role of MIF in inflammatory disease, the chemical space
explored by this approach is limited and molecules that modu-
late MIF activity via alternative mechanisms are likely to have
been overlooked.
Based on the premise that HTS of chemical libraries should
facilitate the exploration of biologically relevant chemical
FIGURE 11.Overriding of glucocorticoid-mediated inhibition of cytokine
production. RAW 264.7 macrophages were preincubated for 1 h with or
without dexamethasone (Dex, 100 nM), MIF (100 ng/ml), and A, ISO-1 (50M),
ebselen, HCLP, bithionol, MDPI894, and dichorophene; or B, compounds 1, 2,
3, 4, 5, 9, and 11 (all at 10 M) before stimulation with 100 ng/ml of LPS.
Cell-free supernatantswere collected after 4 h to quantify the concentrations
of TNF. Data shown are mean  S.D. of triplicate samples from one experi-
ment and are representative of two independent experiments.
FIGURE 12.MIF-mediated activation of AKT phosphorylation and inhibi-
tion with selectedMIF inhibitors. HeLa cells were incubated for 2 h with or
without 50 ng/ml of recombinant human MIF in the presence or absence of
ebselen, HCLP, or LY294002 (1, 10, and 100 M). AKT phosphorylation was
measured using the Alpha screen technology. Data are mean S.D. of tripli-
cate samples from two representative experiments. **, p  0.01 compared
with DMSO; and ¥¥, p  0.01 compared with MIF plus DMSO used at equal
concentration using the Student-Neuman-Keuls test.
FIGURE 13. Ebselen acts as a hyper-agonist ofMIF-mediated chemotaxis.
Calcein-stained day-14 EPCs were preincubatedwith 10M ebselen or HCLP,
added to the upper chamber of a transwell device, and subjected to a che-
motactic gradient of 10 ng/ml of MIF added to the lower chamber. Migration
was followed for 3 h. PBS and 0.1%DMSOwere used as negative controls. The
chemotactic index is plotted, with the number of cells migrated toward the
buffer set to a value of 1.0. Data aremean S.D. of three independent exper-
iments performed with day-14 EPCs and were confirmed further with n 2
additional experiments with day-7 EPCs (data not shown). Statistical signifi-
cance for the hyper-agonistic effect of ebselen is indicated (p 0.02).
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spaces, we developed an activity-based HTS assay that enables
the identification of different classes of potent and selective
inhibitors of MIF, thus facilitating the exploration of a much
larger chemical space. This approach complements current
strategies focused on targeting the tautomerase active site using
structure-based design strategies. In addition to active site
inhibitors, the use of the activity-based HTS assay should facil-
itate the identification of molecules that inactivate or modulate
the activity of MIF by alternative mechanisms, including allo-
steric inhibition, destabilization/dissociation of the active tri-
mer, or covalent modification of the catalytic N-terminal pro-
line residue.
Despite decent reproducibility of the tautomerase assay,
there have been no reports in the literature of MIF HTS tau-
tomerase assays. Initial efforts to developHTSwere abandoned
due to the reported instability of the D-dopachrome substrate
(66), and most recent efforts have relied primarily on in silico
HTS approaches focused on the catalytic site of MIF (66, 67).
We investigated the stability of the substrate and found screen-
ing conditions under which the substrate is stable and suitable
for HTS. As a proof of concept, we first screened a library of
1040 FDA-approved compounds containing a diverse set of
drugs, 85%ofwhich aremarketed in awide range of therapeutic
areas and include anti-inflammatory and analgesic drugs. We
reasoned that the identification of biologically active com-
pounds with known toxicity, pharmacokinetic properties, and
biological activities in vivo should accelerate the development
of clinically relevant MIF inhibitors. Second, we screened the
Maybridge library containing 14,400 compounds. Different
classes of MIF inhibitors that exert their effects via distinct
mechanisms were discovered and validated using a battery of
biochemical and biophysical methods.
Active Site-directed Irreversible Inhibitors of MIF—Blocking
MIF activity via covalent modification of the N-terminal cata-
lytic Pro1 residue was previously seen withNAPQI (37). Amass
shift was detected in rat MIF extracted from liver post-NAPQI
administration. NAPQI-modified MIF failed to override the
effect of the glucocorticoids dexamethasone (37).However, due
to its toxicity no further clinical studies were performed with
NAPQI (42). Another covalent modifier, which was identified
by virtual screening, called 4-iodo-6-phenylpyrimidine, was
also shown to inhibit MIF tautomerase activity via irreversible
modification at the N-terminal proline (33). We recently
reported a newclass of isothiocyanate-based covalentmodifiers
of Pro1 inMIF and showed that they selectively modify catalyt-
ically active forms ofMIF and blockCD74 receptor binding and
MIF-mediated phosphorylation of AKT. Herein, we report the
identification and characterization of several novel irreversible
inhibitors of MIF, the majority of which have potency in the
range of 0.2 to 5.55M (Table 1). The 12 covalentmodifiers can
be grouped into four different classes of reactive electrophiles
that react with the secondary amine of the N-terminal proline
resulting in amide bond formation and loss ofMIF tautomerase
activity.
Non-covalent Inhibitors of MIF—In addition to covalent
modifiers, our screening identified four novel chemical classes
(compounds 3, 9, 11, and HCLP) of reversible MIF inhibitors
with IC50 values ranging from 0.2 to 5.5 M. The slow confor-
mational exchange observed for compound 9, but not for com-
pound 3, suggests a higher affinity of compound 9 for MIF, in
agreement with the KD values. NMR titration demonstrated a
chemical shift deviation with two sequential changes: a mild
interaction followed by a conformational change of MIF.
Increasing molar ratios of compound 9 induces intermediate
exchange of conformation, which implies higher affinity of
compound 9 for MIF. On the other hand, upon titration with
compounds 3 or 11, many residues located in the subunit-sub-
unit interface and enzymatic active site are shifted that may
explain a competition with the substrate. Taken together, sim-
ilar residues of humanMIF are involved in the interaction with
HCLP and compounds 3, 9, and 11, indicating that these four
inhibitors have a similar binding mode.
Inhibition ofMIF Enzymatic ActivityMayNot Be Sufficient to
Block Its Cellular Functions—Our goal is to identify novel
inhibitors that target specific ormultiple activities ofMIF, such
as its tautomerase activity, CD74 receptor binding, and/or its
interactionwith other proteins. However, the notion thatmany
of the cellular functions of MIF, such as receptor binding, do
not involve tautomerase activity (68), combined with observa-
tions from x-ray structures showing small changes in MIF
structure upon binding to inhibitors (69, 70), suggest that inhi-
bition of the enzymatic activity of MIF alone is not sufficient to
block all of its adverse effects. Similarly, neutralization with
anti-MIF antibodies does not appear to affect the enzymatic
activity of MIF.5 Therefore, discovering novel compounds that
can target both activities by inhibiting the enzymatic activity
and blocking CD74 receptor binding or binding to its CXC
receptors ofMIF, should constitute amore effective strategy for
interfering and/or neutralizingMIF activities. Given that oligo-
merization, more specifically trimer formation, is essential for
MIF tautomerase activity and its binding to CD74, we hypoth-
esized that this targeting could be achieved using molecules
that interfere withMIF oligomerization or induce trimer disso-
ciation. In fact, dissociation of the MIF trimer by ebselen
resulted in disruption of critical proinflammatory actions of
MIF (Fig. 12). As CD74 also forms a trimeric structure and
because MIF-stimulated AKT phosphorylation is mediated by
interactions with CD74, this implies that disruption of MIF
trimers could interfere with MIF/CD74-dependent inflamma-
tory and survival pathways. In contrast, MIF trimer-disrupting
compounds acted in a hyper-agonistic fashion inMIF/CXCR2-
mediated recruitment processes, indicating that such inflam-
matory pathways might capitalize on the use of the MIF mon-
omer rather than the trimer. One might thus hypothesize that
in such settings the MIF monomer rather than the trimer is
crucial. This hypothesis can be tested using the N110Cmutant
(Fig. 10), which forms stable cross-linked trimer in solution.
Although modulating protein-protein interactions using
small molecules remains challenging due to the extensive
nature of interactions at the interfaces of interacting proteins,
our studies suggest an alternative strategy for disrupting pro-
tein-protein interactions by specific targeting andmodification
of key protein residues. Using single sitemutagenesis and thiol-
5 H. Ouertatani-Sakouhi and H. A. Lashuel, unpublished results.
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specific alkylation strategies, we demonstrated conclusively
that covalentmodification ofMIF by ebselen occurs atmultiple
cysteine residues and inducesMIF dissociation,misfolding, and
aggregation. To test this hypothesis, we generated a stable di-
sulfide-linked trimeric mutant of MIF (N110C) and showed
that this mutant is modified by ebselen, but does not undergo
aggregation. These findings are consistent with ebselen-in-
duced trimer-to-monomer dissociation as the rate-limiting
step. Induction of aggregation upon covalent modification of
cysteines has been reported as a common feature of the P450
enzymes (71). Covalent modification of tubulin and the P450
apoprotein by benzyl isothiocyanate results in inhibition of
tubulin polymerization, loss of P450 activity, and aggrega-
tion of both proteins in a dose- and time-dependent manner.
We hypothesized that covalent modification of cysteine res-
idues in MIF may induce conformational changes that result
in the exposure of hydrophobic surfaces, which ultimately
leads to protein aggregation. To determine whether MIF
aggregation induced by ebselen is mediated by formation of
disulfide bonds or misfolding of the proteins, we evaluated
the solubility and reversibility of these aggregates upon
treatment with reducing agents and/or SDS. We observed
that addition of dithiothreitol or other reducing agents such
as Tris(2-carboxyethyl)phosphine results only in partial
recovery of monomeric MIF (supplemental Fig. 6A). How-
ever, nearly complete recovery is observed when the MIF
aggregates are re-solubilized in SDS. These findings suggest
that MIF aggregation is driven by noncovalent interactions
and not simply disulfide-mediated polymerization of the
protein. This is consistent with the fact that stable mono-
meric MIF have not been reported and MIF aggregation is
observed under conditions that destabilize the trimer.
Ebselen,2-phenyl-1,2-benzisoselenazol-3(2H)-one, isknownto
act as an antioxidant and possess anti-inflammatory proper-
ties. In addition, several studies have shown that ebselen is
neuroprotective in different animal and cellular models of
neurodegenerative diseases (e.g. Parkinson disease (72–74))
and glutamate-induced neurotoxicity (74). Our findings that
ebselen modifications occurs at the Se-S bond is consistent
with previous studies, which have documented that ebselen
inhibition of several enzymes and receptors is mediated by
directly reacting with thiol groups resulting in a modifica-
tion of their oxidation state and/or conformational proper-
ties. Ebselen interacts with cysteine residues in proteins
resulting in the formation of disulfide bond formation and an
ebselen diselenide product (57). Among the proteins that
have been shown to be inhibited by mechanisms involving
direct ebselen modifications of cysteine residues are
zinc metallothionein (75), glutathione S-transferase (76),
NADPH oxidase (77), protein kinase C (78), inositol 1,4,5-
trisphosphate receptor (79), N-methyl-D-asparatate recep-
tor, and membrane calcium-ATPase (80). Consistent with
this mechanism, studies in our laboratory demonstrate that the
ebselen-induced aggregation of MIF is blocked in the presence
of dithiothreitol and GSH (supplemental Fig. S6B). While this
article was under review, a study by Terentis et al. (81) demon-
strated that ebselen is a potent inhibitor of indoleamine 2,3-
dioxygenase. The activity of ebselen was shown to be mediated
by direct interaction with multiple cysteine residues of
indoleamine 2,3-dioxygenase, which results in significant
structural changes that alter the active site heme and substrate
binding to indoleamine 2,3-dioxygenase. Similar to our obser-
vations with MIF, alkylation of cysteine residues or removal of
indoleamine 2,3-dioxygenase-bound ebselen, via addition of
reducing agents, abolished the inhibitory activity of ebselen
(supplemental Fig. S6).
Although, some of the antioxidant and neuroprotective
properties of ebselen have been attributed to its ability tomimic
the activity of glutathione (GSH) peroxidase (82, 83), themech-
anisms underlying its anti-inflammatory activity remain
unknown. The data presented in this article are consistent with
previous reports and provide additional evidence that ebselen
interaction with inflammatory proteins goes beyond simply
modification of these proteins. Further studies are required to
determine whether ebselen modulation of the activities of MIF
contributes to its anti-inflammatory activity. Studies in animal
models as well as in humans have shown that ebselen exhibits
low toxicity (52, 58) and is currently in clinical trials for the
treatment of ischemic stroke (52) and subarachnoid hemor-
rhage (58).
In conclusion, we developed a simple, robust, and highly
reproducible assay that allows for rapid and reliable screen-
ing of large chemical libraries to identify diverse and highly
potent inhibitors of MIF enzymatic and biological activities.
We described the discovery and characterization of 12 novel
chemical classes of MIF inhibitors that exert their effects via
distinct mechanisms. The mechanism of action of these
inhibitors was determined and validated using a battery of
biochemical and biophysical methods as well as by the gen-
eration of novel MIF mutants. The majority of the com-
pounds identified displayed low IC50 values (0.2–6 M) and
toxicity, thus making them ideal lead candidates for fol-
low-up medicinal chemistry efforts and in vivo studies.
Importantly, all inhibitors demonstrated total inhibition of
MIF-mediated glucocorticoid overriding. The two inhibitors
ebselen and HCLP inhibit MIF-mediated AKT phosphory-
lation, whereas ebselen, a trimer-disrupting inhibitor, addi-
tionally acted as a potent hyper-agonist in MIF-mediated
chemotactic migration. Some of the lead inhibitors are
already approved drugs with known safety and oral bioavail-
ability profiles. Our discovery of ebselen as the first example
of small molecule inhibitor of MIF, which acts by selective
modification and disruption of the trimer, reveal a novel
mechanism for targeting protein-protein interactions. Fur-
thermore, this discovery has significant implications for
developing more effective drugs that could target multiple
proinflammatory activities meditated by the MIF trimer.
Together, these results provide the foundation for future
studies to determine the efficacy of these compounds in vivo
and compare their efficacy to anti-MIF neutralizing antibodies
using established experimental models of inflammatory and
autoimmune diseases and tumorigenesis (35, 68). Furthermore,
the diversity of chemical structures and mechanisms of action
of our inhibitors makes them ideal mechanistic probes and
diagnostic tools for elucidating the structure-function relation-
ships of MIF and to further determine the role of the catalytic
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activity of MIF in regulating the function(s) of MIF in health
and disease.
Acknowledgments—We thank Dr. Gerardo Turcatti, Pierre-Olivier
Regamey, Dr. Damiano Banfi, andDr.Marc Chambon from the EPFL
biomolecular screening facility for advice and assistance in auto-
mated screening and data analysis. We also thank Dr. Marc Moni-
atte, Diego Chiappe, and Je´rome Vialaret from the proteomic facility
for assistance and Marlies Knaup-Reymond and Anne-Laure
Schiesser from technical assistance.We thankDr. RichardBucala, Dr.
Loay Awad, Dr. Sara Butterfield, and Dr. Hongqi Lue for valuable
discussions.
REFERENCES
1. Bloom, B. R., and Bennett, B. (1966) Science 153, 80–82
2. David, J. R. (1966) Proc. Natl. Acad. Sci. U.S.A. 56, 72–77
3. Weiser,W. Y., Temple, P. A., Witek-Giannotti, J. S., Remold, H. G., Clark,
S. C., and David, J. R. (1989) Proc. Natl. Acad. Sci. U.S.A. 86, 7522–7526
4. Bernhagen, J., Calandra, T., Mitchell, R. A., Martin, S. B., Tracey, K. J.,
Voelter, W., Manogue, K. R., Cerami, A., and Bucala, R. (1993) Nature
365, 756–759
5. Calandra, T., and Roger, T. (2003) Nat. Rev. Immunol. 3, 791–800
6. Lolis, E., and Bucala, R. (2003) Expert Opin. Ther. Targets 7, 153–164
7. Leech, M., Metz, C., Hall, P., Hutchinson, P., Gianis, K., Smith, M.,
Weedon, H., Holdsworth, S. R., Bucala, R., and Morand, E. F. (1999) Ar-
thritis Rheum. 42, 1601–1608
8. Mikulowska, A.,Metz, C. N., Bucala, R., andHolmdahl, R. (1997) J. Immu-
nol. 158, 5514–5517
9. Lan, H. Y., Bacher, M., Yang, N., Mu,W., Nikolic-Paterson, D. J., Metz, C.,
Meinhardt, A., Bucala, R., and Atkins, R. C. (1997) J. Exp. Med. 185,
1455–1465
10. Brown, F. G., Nikolic-Paterson, D. J., Hill, P. A., Isbel, N. M., Dowling, J.,
Metz, C. M., and Atkins, R. C. (2002) J. Am. Soc. Nephrol. 13, Suppl. 1,
S7–13
11. Yabunaka,N., Nishihira, J.,Mizue, Y., Tsuji,M., Kumagai,M., Ohtsuka, Y.,
Imamura, M., and Asaka, M. (2000) Diabetes Care 23, 256–258
12. Zernecke, A., and Weber, C. (2010) Cardiovasc Res. 2, 192–201
13. Calandra, T., Echtenacher, B., Roy, D. L., Pugin, J.,Metz, C. N., Hu¨ltner, L.,
Heumann, D., Ma¨nnel, D., Bucala, R., and Glauser, M. P. (2000)Nat. Med.
6, 164–170
14. Beishuizen, A., Thijs, L. G., Haanen, C., and Vermes, I. (2001) J. Clin.
Endocrinol. Metab. 86, 2811–2816
15. Emonts, M., Sweep, F. C., Grebenchtchikov, N., Geurts-Moespot, A.,
Knaup, M., Chanson, A. L., Erard, V., Renner, P., Hermans, P. W., Hazel-
zet, J. A., and Calandra, T. (2007) Clin. Infect Dis. 44, 1321–1328
16. Rossi, A. G., Haslett, C., Hirani, N., Greening, A. P., Rahman, I., Metz,
C. N., Bucala, R., andDonnelly, S. C. (1998) J. Clin. Invest. 101, 2869–2874
17. Mizue, Y., Ghani, S., Leng, L.,McDonald, C., Kong, P., Baugh, J., Lane, S. J.,
Craft, J., Nishihira, J., Donnelly, S. C., Zhu, Z., and Bucala, R. (2005) Proc.
Natl. Acad. Sci. U.S.A. 102, 14410–14415
18. Donnelly, S. C., Haslett, C., Reid, P. T., Grant, I. S., Wallace, W. A., Metz,
C. N., Bruce, L. J., and Bucala, R. (1997) Nat. Med. 3, 320–323
19. Bucala, R., and Donnelly, S. C. (2007) Immunity 26, 281–285
20. Rendon, B. E., Willer, S. S., Zundel, W., and Mitchell, R. A. (2009) Exp.
Mol. Pathol. 86, 180–185
21. Zhang, M., Aman, P., Grubb, A., Panagopoulos, I., Hindemith, A., Rosen-
gren, E., and Rorsman, H. (1995) FEBS Lett. 373, 203–206
22. Rosengren, E., Bucala, R., Aman, P., Jacobsson, L., Odh, G., Metz, C. N.,
and Rorsman, H. (1996)Mol. Med. 2, 143–149
23. Bendrat, K., Al-Abed, Y., Callaway, D. J., Peng, T., Calandra, T., Metz,
C. N., and Bucala, R. (1997) Biochemistry 36, 15356–15362
24. Swope, M., Sun, H. W., Blake, P. R., and Lolis, E. (1998) EMBO J. 17,
3534–3541
25. Chook, Y. M., Gray, J. V., Ke, H., and Lipscomb, W. N. (1994) J. Mol. Biol.
240, 476–500
26. Subramanya, H. S., Roper, D. I., Dauter, Z., Dodson, E. J., Davies, G. J.,
Wilson, K. S., and Wigley, D. B. (1996) Biochemistry 35, 792–802
27. Stivers, J. T., Abeygunawardana, C., Mildvan, A. S., Hajipour, G., and
Whitman, C. P. (1996) Biochemistry 35, 814–823
28. Suzuki, M., Sugimoto, H., Nakagawa, A., Tanaka, I., Nishihira, J., and Sa-
kai, M. (1996) Nat. Struct. Biol. 3, 259–266
29. Sun, H.W., Bernhagen, J., Bucala, R., and Lolis, E. (1996) Proc. Natl. Acad.
Sci. U.S.A. 93, 5191–5196
30. Swope,M.D., Sun,H.W., Klockow, B., Blake, P., and Lolis, E. (1998) J. Biol.
Chem. 273, 14877–14884
31. Rosengren, E., Aman, P., Thelin, S., Hansson, C., Ahlfors, S., Bjo¨rk, P.,
Jacobsson, L., and Rorsman, H. (1997) FEBS Lett. 417, 85–88
32. Morand, E. F., Leech, M., and Bernhagen, J. (2006)Nat. Rev. Drug. Discov.
5, 399–410
33. Winner, M., Meier, J., Zierow, S., Rendon, B. E., Crichlow, G. V., Riggs, R.,
Bucala, R., Leng, L., Smith, N., Lolis, E., Trent, J. O., and Mitchell, R. A.
(2008) Cancer Res. 68, 7253–7257
34. Zhang, X., and Bucala, R. (1999) Bioorg. Med. Chem. Lett. 9, 3193–3198
35. Al-Abed, Y., Dabideen, D., Aljabari, B., Valster, A., Messmer, D., Ochani,
M., Tanovic, M., Ochani, K., Bacher, M., Nicoletti, F., Metz, C., Pavlov,
V. A.,Miller, E. J., and Tracey, K. J. (2005) J. Biol. Chem. 280, 36541–36544
36. Garai, J., and Lo´ra´nd, T. (2009) Curr. Med. Chem. 16, 1091–1114
37. Senter, P. D., Al-Abed, Y., Metz, C. N., Benigni, F., Mitchell, R. A.,
Chesney, J., Han, J., Gartner, C. G., Nelson, S. D., Todaro, G. J., and Bucala,
R. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 144–149
38. Lubetsky, J. B., Dios, A., Han, J., Aljabari, B., Ruzsicska, B., Mitchell, R.,
Lolis, E., and Al-Abed, Y. (2002) J. Biol. Chem. 277, 24976–24982
39. Dios, A., Mitchell, R. A., Aljabari, B., Lubetsky, J., O’Connor, K., Liao, H.,
Senter, P. D., Manogue, K. R., Lolis, E., Metz, C., Bucala, R., Callaway, D. J.,
and Al-Abed, Y. (2002) J. Med. Chem. 45, 2410–2416
40. Dagia, N. M., Kamath, D. V., Bhatt, P., Gupte, R. D., Dadarkar, S. S., Fon-
seca, L., Agarwal, G., Chetrapal-Kunwar, A., Balachandran, S., Srinivasan,
S., Bose, J., Pari, K., B-Rao, C., Parkale, S. S., Gadekar, P. K., Rodge, A. H.,
Mandrekar, N., Vishwakarma, R. A., and Sharma, S. (2009) Eur. J. Phar-
macol. 607, 201–212
41. Balachandran, S., Rodge, A., Gadekar, P. K., Yadav, V. N., Kamath, D.,
Chetrapal-Kunwar, A., Bhatt, P., Srinivasan, S., Sharma, S., Vishwakarma,
R. A., and Dagia, N. M. (2009) Bioorg. Med. Chem. Lett. 16, 4773–4776
42. Dabideen, D. R., Cheng, K. F., Aljabari, B., Miller, E. J., Pavlov, V. A., and
Al-Abed, Y. (2007) J. Med. Chem. 50, 1993–1997
43. El-Turk, F., Cascella, M., Ouertatani-Sakouhi, H., Narayanan, R. L., Leng,
L., Bucala, R., Zweckstetter, M., Rothlisberger, U., and Lashuel, H. A.
(2008) Biochemistry 40, 10740–10756
44. El-Turk, F., Fauvet, B., Min-kyu, C., Ouertatani-Sakouhi, H., Neri, M.,
Cascella, M., Rothlisberger, U., Zweckstetter, M., and Lashuel, H. A.
(2010) Biochemistry, in press
45. Bernhagen, J., Mitchell, R. A., Calandra, T., Voelter, W., Cerami, A., and
Bucala, R. (1994) Biochemistry 33, 14144–14155
46. Kleemann, R., Mischke, R., Kapurniotu, A., Brunner, H., and Bernhagen, J.
(1998) FEBS Lett. 430, 191–196
47. Zhang, J. H., Chung, T. D., andOldenburg, K. R. (1999) J. Biomol. Screen 4,
67–73
48. Liu, M., Dobson, B., Glicksman, M. A., Yue, Z., and Stein, R. L. (2010)
Biochemistry 49, 2008–2017
49. Philo, J. S., Yang, T. H., and LaBarre,M. (2004)Biophys. Chem. 108, 77–87
50. Schuck, P. (2000) Biophys. J. 78, 1606–1619
51. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A.
(1995) J. Biomol. NMR 6, 277–293
52. Yamaguchi, T., Sano, K., Takakura, K., Saito, I., Shinohara, Y., Asano, T.,
and Yasuhara, H. (1998) Stroke 29, 12–17
53. Hurt, S., and Titus, D. (2010)Optimization of an AlphaScreen Sure Fire
Cell-based Assay to Measure Phosphorylation of Akt1/2/3 Isoforms at Ser-
473, Application Note, PerkinElmer Life Sciences, Waltham, MA
54. Simons,D., Grieb,G.,Hristov,M., Pallua,N.,Weber, C., Bernhagen, J., and
Steffens, G. (2010) J. Cell. Mol. Med., in press
55. Nishihira, J., Fujinaga, M., Kuriyama, T., Suzuki, M., Sugimoto, H., Naka-
gawa, A., Tanaka, I., and Sakai,M. (1998)Biochem. Biophys. Res. Commun.
243, 538–544
MIF Inhibition
AUGUST 20, 2010•VOLUME 285•NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 26597
 at EPFL Scientific Inform
ation and Libraries, on Novem
ber 10, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
56. Ouertatani-Sakouhi, H., El-Turk, F., Fauvet, B., Roger, T., Le Roy, D.,
Karpinar, D. P., Leng, L., Bucala, R., Zweckstetter, M., Calandra, T., and
Lashuel, H. A. (2009) Biochemistry 41, 9856–9870
57. Schewe, T. (1995) Gen. Pharmacol. 26, 1153–1169
58. Saito, I., Asano, T., Sano, K., Takakura, K., Abe, H., Yoshimoto, T., Kiku-
chi, H., Ohta, T., and Ishibashi, S. (1998) Neurosurgery 42, 269–277; dis-
cussion 277–268
59. Sakurai, T., Kanayama,M., Shibata, T., Itoh, K., Kobayashi, A., Yamamoto,
M., and Uchida, K. (2006) Chem. Res. Toxicol. 19, 1196–1204
60. Daiber, A., Zou, M. H., Bachschmid, M., and Ullrich, V. (2000) Biochem.
Pharmacol. 59, 153–160
61. Kleemann, R., Kapurniotu, A., Frank, R. W., Gessner, A., Mischke, R.,
Flieger, O., Ju¨ttner, S., Brunner, H., and Bernhagen, J. (1998) J. Mol. Biol.
280, 85–102
62. Calandra, T., Bernhagen, J., Metz, C. N., Spiegel, L. A., Bacher, M., Don-
nelly, T., Cerami, A., and Bucala, R. (1995) Nature 377, 68–71
63. Roger, T., Chanson, A. L., Knaup-Reymond, M., and Calandra, T. (2005)
Eur. J. Immunol. 35, 3405–3413
64. Lue, H., Thiele, M., Franz, J., Dahl, E., Speckgens, S., Leng, L., Fingerle-
Rowson, G., Bucala, R., Lu¨scher, B., and Bernhagen, J. (2007)Oncogene 26,
5046–5059
65. Bernhagen, J., Krohn, R., Lue, H., Gregory, J. L., Zernecke, A., Koenen,
R. R., Dewor, M., Georgiev, I., Schober, A., Leng, L., Kooistra, T., Fingerle-
Rowson, G., Ghezzi, P., Kleemann, R., McColl, S. R., Bucala, R., Hickey,
M. J., and Weber, C. (2007) Nat. Med. 13, 587–596
66. Orita, M., Yamamoto, S., Katayama, N., and Fujita, S. (2002)Curr. Pharm.
Des. 8, 1297–1317
67. Cournia, Z., Leng, L., Gandavadi, S., Du, X., Bucala, R., and Jorgensen,
W. L. (2009) J. Med. Chem. 52, 416–424
68. Fingerle-Rowson, G., Kaleswarapu, D. R., Schlander, C., Kabgani, N.,
Brocks, T., Reinart,N., Busch, R., Schu¨tz, A., Lue,H., Du,X., Liu, A., Xiong,
H., Chen, Y., Nemajerova, A., Hallek, M., Bernhagen, J., Leng, L., and
Bucala, R. (2009)Mol. Cell. Biol. 29, 1922–1932
69. Crichlow, G. V., Lubetsky, J. B., Leng, L., Bucala, R., and Lolis, E. J. (2009)
Biochemistry 48, 132–139
70. Orita, M., Yamamoto, S., Katayama, N., Aoki, M., Takayama, K., Yam-
agiwa, Y., Seki, N., Suzuki, H., Kurihara, H., Sakashita, H., Takeuchi, M.,
Fujita, S., Yamada, T., and Tanaka, A. (2001) J. Med. Chem. 44, 540–547
71. Solano, F., Hearing, V. J., and García-Borro´n, J. C. (2000)Neurotox. Res. 1,
153–169
72. Dhanasekaran, M., Uthayathas, S., Karuppagounder, S. S., Parameshwa-
ran, K., Suppiramaniam, V., Ebadi, M., and Brown-Borg, H. M. (2006)
Brain. Res. 1118, 251–254
73. Moussaoui, S., Obinu, M. C., Daniel, N., Reibaud, M., Blanchard, V., and
Imperato, A. (2000) Exp. Neurol. 166, 235–245
74. Porciu´ncula, L. O., Rocha, J. B., Boeck, C. R., Vendite, D., and Souza, D. O.
(2001) Neurosci. Lett. 299, 217–220
75. Jacob, C., Maret, W., and Vallee, B. L. (1998) Biochem. Biophys. Res. Com-
mun. 248, 569–573
76. Nikawa, T., Schuch, G., Wagner, G., and Sies, H. (1994) Biochem. Phar-
macol. 47, 1007–1012
77. Wang, J. F., Komarov, P., Sies, H., and de Groot, H. (1992)Hepatology 15,
1112–1116
78. Cotgreave, I. A., Duddy, S. K., Kass, G. E., Thompson, D., andMolde´us, P.
(1989) Biochem. Pharmacol. 38, 649–656
79. Dimmeler, S., Bru¨ne, B., and Ullrich, V. (1991) Biochem. Pharmacol. 42,
1151–1153
80. Ying, J., Tong, X., Pimentel, D. R.,Weisbrod, R.M., Trucillo,M. P., Adachi,
T., and Cohen, R. A. (2007) Arterioscler. Thromb. Vasc. Biol. 27, 783–790
81. Terentis, A. C., Freewan, M., Sempe´rtegui Plaza, T. S., Raftery, M. J.,
Stocker, R., and Thomas, S. R. (2010) Biochemistry 49, 591–600
82. Wendel, A., Fausel, M., Safayhi, H., Tiegs, G., and Otter, R. (1984) Bio-
chem. Pharmacol. 33, 3241–3245
83. Sies, H. (1993) Free Radic. Biol. Med. 14, 313–323
MIF Inhibition
26598 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 34•AUGUST 20, 2010
 at EPFL Scientific Inform
ation and Libraries, on Novem
ber 10, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
